INTRODUCTION
============

Many cancers, cardiovascular disease, and acute and chronic fibrosis are accompanied by increased extracellular matrix deposition and increased tissue stiffness ([@B47]). Normal physical properties of tissues within the body have great diversity, with stiffness ranging from very soft (brain, fat tissue) to rigid (bone) ([@B22]). Cells interpret their environment through force sensing by pulling on surrounding matrix to measure the levels of stiffness and then respond to these physical cues in their tissue microenvironment through activation of mechanosensing signaling pathways. Signals transduced by sensing tissue stiffness impact cell fate decisions by providing instructive differentiation signals. Mechanosensing is regulated and operative during development, leading to diversity in differentiation and organogenesis/morphogenesis, and during postnatal life for maintenance of tissue homeostasis and facilitating regeneration and wound healing processes ([@B32]; [@B36]; [@B14]). It has been suggested that a mechanosignaling stimulus alone can be sufficient to direct cell differentiation; for example, mesenchymal progenitor cells sensing an environment with the mechanical properties of nascent bone tissue will respond by undergoing osteogenic differentiation ([@B32]). Recently, it has become widely recognized that altered mechanosensing can also contribute to the pathogenesis of genetic and nongenetic diseases ([@B47]; [@B25]; [@B10]; [@B57]; [@B52]); however, whether heterotopic ossification (HO), a condition in which extraskeletal bone forms within soft connective tissues ([@B70]), could be influenced by altered force-sensing and differential interpretation of substrate stiffness remains undetermined.

Fibrodysplasia ossificans progressiva (FOP; MIM \#135100) is a rare genetic disease that forms extensive and progressive postnatal ossification within soft tissues ([@B86]). The heterotopic bone that forms within soft connective tissues in FOP is normal bone tissue by all evaluated criteria; its aberration lies in the lost regulation of cell fate determination. Mutations in the bone morphogenetic proteins (BMP) type I receptor ACVR1 (Activin A receptor, type 1; alias: ALK2) cause FOP, and all patients with a classic clinical manifestation of the disease possess a recurrent heterozygous c.617G\>A (R206H) mutation ([@B87]; [@B55]). This single-nucleotide substitution results in overactivation of the BMP signaling pathway ([@B34]; [@B83]; [@B96]; [@B40]). The BMP pathway is well established as promoting cartilage and bone formation ([@B75]; [@B82]), and the ACVR1 R206H mutation has been shown to enhance chondrogenesis and osteogenesis ([@B83]; [@B96]; [@B23]; [@B40]). Heterotopic ossification in FOP, as well as in more common nonhereditary HO ([@B74]; [@B86]), forms through progressive tissue and cellular events that culminate in bone tissue formation within skeletal muscle and other soft connective tissues; these bone-forming lesions are often initiated by tissue damage. In the absence of overt injury, new bone formation in FOP patients occurs spontaneously and episodically, interspersed by apparent periods of quiescence with no HO formation ([@B53]; [@B85]). These clinical observations support that factors in addition to the genetic mutation modulate the cellular activity of the mutant receptor to strongly influence disease progression.

Heterotopic ossification in FOP forms through a well-described series of changes within the tissue ([@B86]; [@B13]; [@B19]). In response to injury, initial steps of wound healing in FOP tissue appear to be normal, including an early immune response that leads to tissue degradation and removal of damaged tissue. The transition from tissue degradation to regeneration during normal wound healing is a fibroproliferative stage characterized by up-regulated extracellular matrix (ECM) production and remodeling. However, in FOP tissue this trajectory diverges when, instead of repairing and regenerating the injured tissue, progenitor cells aberrantly differentiate to cartilage and bone cells and endochondral bone is formed ([@B54]; [@B86]; [@B23]; [@B19]). Alterations in the physical and mechanical properties of the tissue during this stage, and altered sensing of the tissue microenvironment by mutant progenitor cells that are primed to chondro-osseous differentiation by the underlying *ACVR1* mutation, may have major, yet unrecognized, roles in promoting HO by creating a tissue microenvironment that is permissive and/or inductive for chondrogenic and osteogenic differentiation.

In this study, we examined in vivo stiffness and ECM properties of *Acvr1^R206H^* mutant tissue in response to injury to determine whether the physical/mechanical microenvironment of the tissue where HO forms is altered. Additionally, we determine whether the mutation modulates mechanosensing and mechanosignaling by investigating the ability of cells expressing the FOP mutation to properly sense and respond to the mechanical cues in their microenvironment. Our data support that both changes in the tissue microenvironment and the ability of cells to sense their environment are altered by the FOP *Acvr1^R206H^* mutation.

RESULTS
=======

Tissue rigidity is increased in fibroproliferative areas following injury of Acvr1^R206H/+^ muscle
--------------------------------------------------------------------------------------------------

Muscle injury frequently triggers heterotopic bone formation in FOP patients, suggesting an aberrant wound healing response in the presence of the *ACVR1^R206H^* mutation. Expression of *Acvr1^R206H/+^* in a knock-in mouse model of FOP recapitulates all key clinical features of the disease including HO formation in response to muscle injury ([@B13], [@B12]; [@B19]). To investigate changes in skeletal muscle tissue properties in response to injury, we treated *Acvr1^R206H/+^* knock-in mice with cardiotoxin ([Figure 1A](#F1){ref-type="fig"}). Cardiotoxin (CTX) leads to rapid muscle damage and muscle degradation that is accompanied by an inflammatory response; this catabolic phase is followed by the onset of an anabolic, reconstruction phase characterized by activation of muscle stem cells (e.g., satellite cells) that proliferate, differentiate, and subsequently form new muscle fibers in wild-type tissue ([@B21]; [@B15]; [@B98]; [@B24]).

![Increased fibroproliferative tissue stiffness in response to skeletal muscle injury in *Acvr1^R206H/+^* mice. (A) Timeline of experimental procedure. The *Acvr1^R206H^* mutation was expressed in conditional Acvr1^R206H/+^ mice through doxycycline treatment 3 d prior to injection with cardiotoxin or PBS (uninjured control). Littermate controls were treated equivalently. (B) H&E staining of sections from PBS-injected or CTX-injured quadriceps showing areas of healthy muscle and fibroproliferation (arrow) 4 d post--injection of FOP mice or littermate controls. Scale bar represents 100 µm. (C) Enlarged images from insets in B. Scale bar: 50 µm. (D) Tissue stiffness was measured via AFM. Consecutive sections demonstrate increased rigidity of fibroproliferative areas (FP) in FOP lesions compared with healthy muscle (M). Graph represents mean ± SEM for *N* = 5--18 (in M: 5 \[control\] and 6 \[FOP\]; in FP: 10 \[control\] and 18 \[FOP\]) locations measured across three independently injured limbs. Significance was determined by two-way ANOVA (Bonferroni post test); \**p* \< 0.05.](mbc-30-17-g001){#F1}

To assay lesions in injured muscle from *Acvr1^+/+^* control littermates and *Acvr1^R206H/+^* mice at the fibroproliferative stage, animals were killed at days 4 to 5 post--CTX injury ([Figure 1A](#F1){ref-type="fig"}), a time at which no heterotopic bone or cartilage has yet formed ([@B13]; [@B19]), as verified by H&E staining of the injured tissues. Phosphate-buffered saline (PBS) injection in control and mutant mice ([Figure 1B](#F1){ref-type="fig"}) did not induce muscle injury and served as negative controls. Substantial degeneration of muscle tissue was found after CTX injection in both *Acvr1^R206H/+^* mice and controls. Early stages of wound healing were accompanied by robust fibro­proliferation in both mutant and control littermates ([Figure 1, B and C](#F1){ref-type="fig"}). Tissue stiffness was quantified by measuring Young\'s moduli through atomic force microscopy (AFM) ([@B64]) of consecutive nonfixed tissue cryosections ([Figure 1D](#F1){ref-type="fig"}, left). Stiffness of healthy uninjured muscle was ∼20 kPa, with no significant difference between *Acvr1^R206H/+^* and control littermates ([Figure 1D](#F1){ref-type="fig"}, right). Fibroproliferative regions in injured areas of control littermates showed a \>3.5-fold reduction in rigidity compared with healthy muscle (black columns, [Figure 1D](#F1){ref-type="fig"}, right), consistent with the ongoing turnover of damaged muscular tissue and initial stages of wound healing ([@B45]). Lesions in control littermates were relatively soft (∼6 kPa), indicating that these tissues are at an early wound healing (early fibroproliferation) stage, well before the appearance of repaired muscle fibers. However, at the comparable time point, tissue stiffness in fibroproliferative areas of injured *Acvr1^R206H/+^* tissue was significantly elevated compared with controls, reaching a stiffness of ≥40 kPa, which is ∼2-fold higher ([Figure 1D](#F1){ref-type="fig"}, right, red bars) than healthy uninjured muscle, not unlike the pathological stiffening of tissues that is observed in fibrosis or scar tissue (∼15--100 kPa) ([@B66]; [@B8]) and is a stiffness consistent with previously reported AFM measurements of the osteoid microenvironment within bone ([@B32]). Intact skeletal muscle, located in close proximity to the lesions in the *Acvr1^R206H/+^* CTX-injected group, also scaled to 20 kPa, supporting that tissue stiffening is locally restricted to fibroproliferative areas (Supplemental Figure 1). These results demonstrate that *Acvr1^R206H/+^* preosseous tissues are aberrantly stiffer and indicate that cells at sites of wound repair are actively constructing and experiencing a local microenvironment that has greater mechanical signaling properties than in control tissues.

Differences in ECM composition and collagen organization contribute to stiffer Acvr1 ^R206H/+^ tissue
-----------------------------------------------------------------------------------------------------

The biophysical properties of tissue can be altered by subtle differences in matrix composition and/or organization. During normal wound healing in muscle, fibro/adipogenic progenitors (FAPs) ([@B18]) secrete increased amounts of various collagen isoforms, a process that is correlated with increased tissue stiffening ([@B46]). Collagens are the major component of connective tissue ECM in mammals, forming a structural framework for cells and functioning as a storage system for morphogens and growth factors ([@B77]). Collagen types I and III are the main collagens expressed by myofibroblasts during wound healing ([@B44]; [@B46]; [@B102]; [@B56]). We therefore investigated whether the elevated stiffness within *Acvr1^R206H/+^* lesions is accompanied by altered collagen content and organization within the fibroproliferative tissue.

To quantify changes in collagen production in further detail, we used mouse embryonic fibroblasts (MEFs) as an in vitro system. MEFs have properties of mesenchymal stem/progenitor cells including multipotent lineage potential ([@B62]; [@B35]; [@B81]; [@B23]). We previously demonstrated that *Acvr1^R206H/+^* MEFs can undergo adipogenesis, chondrogenesis, and osteogenesis and that the mutation induces accelerated chondrogenesis and endochondral ossification ([@B23]). *Acvr1^R206H/+^* MEFs also have increased BMP-pSmad1/5/8 pathway activation, a hallmark of FOP patient-derived cells that has been recapitulated and verified in multiple systems ([@B7]; [@B83]; [@B23]).

Total collagens produced by control and *Acvr1^R206H/+^* MEFs were visualized and quantified by picrosirius red staining of cell monolayers and showed increased collagen deposition in *Acvr1^R206H/+^* cells compared with control ([Figure 2A](#F2){ref-type="fig"}). No differences in collagen type I mRNA levels were detected by quantitative reverse transcription-PCR (qRT-PCR) analysis; however, mutant cells expressed elevated collagen type II mRNA compared with controls ([Figure 2B](#F2){ref-type="fig"}). Collagen type III expression appeared to be delayed in *Acvr1^R206H/+^* cells, with lower mRNA levels at earlier time points compared with controls.

![Altered collagen composition in Acvr1^R206H/+^ cells. In vitro analyses of collagen deposition and gene expression were conducted in immortalized MEFs. (A) Sirius red/Fast green staining demonstrated increased collagen deposition in *Acvr1^R206H/+^* (FOP) cells compared with control (*Acvr1^+/+^*). Fast green counterstain was used to normalize to total protein content after extraction. Graph represents mean ± SEM. Results from one representative experiment of three independent experiments are shown. (B) Collagen type I--III mRNA expression was quantified over time by RT-PCR. Data are relative to *Acvr1^+/+^* controls on day 1. *Acvr1^R206H/+^* cells showed increased collagen type II expression (day 1: *n* = 5; day 2: *n* = 3; day 3: *n* = 4; day 4: *n* = 4; day 7: *n* = 3). Graphs represent mean ± SEM. Significance was determined by two-tailed Student\'s *t* test; \**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001.](mbc-30-17-g002){#F2}

To qualitatively assess collagens within control and *Acvr1^R206H/+^* injured muscle, collagens type I, type II, and type III were detected by immunostaining at the fibroproliferative stage ([Figure 3A](#F3){ref-type="fig"}). Counterstaining with hematoxylin or 4',6-diamidino-2-phenylindole (DAPI) was used to identify areas of intact muscle and damaged tissue. No qualitative differences were detected in collagen type I or III deposition in either control or *Acvr1^R206H/+^* tissues at this stage of lesion progression. Collagen type II, a collagen associated with cartilage matrix, is not expressed by fibroblasts ([@B72]) and was not detected in control wounds; however, collagen type II was detected in fibroproliferative lesions of *Acvr1^R206H/+^* tissue, indicating improper collagen production resulting from the mutation following injury ([Figure 3B](#F3){ref-type="fig"}).

![Altered ECM composition and organization in lesions from *Acvr1^R206H/+^* mice. (A, B) Tissues from cardiotoxin injected quadriceps 5 d post--injection of FOP mice or littermate controls were counterstained with (A) hematoxylin after collagen types I and III immunostaining or (B) DAPI after collagen type II detection. *Acvr1^R206H/+^* lesions did not show qualitative differences in collagen type I or III deposition during the fibroproliferative stage, but collagen type II was more highly detected (brown stain). Scale bar represents 100 μm. (C) Representative images from SHG (blue signal) were used to quantify differences in collagen organization (D) between FOP (*n* = 7) and control littermates (*n* = 8) at the fibroproliferative stage. Significance was determined by two-tailed Student\'s *t* test; \**p* = 0.02.](mbc-30-17-g003){#F3}

This modified composition of extracellular matrix produced by *Acvr1^R206H/+^* cells and tissue prompted us to investigate in vivo structural differences more closely using second harmonic generation (SHG) imaging, a powerful approach for visualizing collagen organization in tissues ([@B17]). The degree of collagen organization within the tissue following injury was determined by blinded scoring; higher scores indicate a more organized SHG-positive ECM and lower scores indicate a more disorganized arrangement. A higher degree of collagen organization suggesting increased density of fibrillar collagen was found in *Acvr1^R206H/+^* injured muscle at the fibroproliferative stage compared with control littermates ([Figure 3, C and D](#F3){ref-type="fig"}), indicating advanced organization and maturation. Increased fibrillar density has been correlated with increased tissue stiffness and higher Young\'s modulus ([@B11]; [@B80]; [@B76]), suggesting that changes in collagen organization contributes to the increased lesion stiffness in FOP. These findings suggest that altered ECM composition and organization in *Acvr1^R206H/+^* lesions contribute to redirecting cell fate decision of progenitor cells into chondrogenic and/or osteogenic lineages, although a more detailed mechanism of how this altered content and assembly culminates in increased tissue stiffening remains to be elucidated.

Mechanotransduction pathways are overactivated in Acvr1^R206H/+^ cells
----------------------------------------------------------------------

Cellular behavior of fibroblasts (e.g., differentiation, proliferation, ECM secretion) is strongly influenced by mechanical cues derived from the underlying substrata ([@B103]). Cells translate these physical forces from the microenvironment into biochemical signals that are intracellularly transmitted via multiple mechanoresponsive signaling pathways ([@B95]). The Rho family of small GTPases activates one of the most studied mechanotransduction pathways and Rho signaling is a key regulator of the actin cytoskeleton. Rho cycles among inactive, GDP-bound and -active, and GTP-bound states, consequently regulating the activity of downstream effectors such as Rho kinase (ROCK), a critical regulator of cell contractility ([@B63]). Basal activation of BMP signaling pathways, even in the absence of ligand, also has been shown to regulate cell contractility in mesenchymal stem cells ([@B43], [@B42]).

To determine the influence of the *Acvr1^R206H^* mutation on mechanosignaling, we first evaluated the basal activation level of the Rho/ROCK pathway in *Acvr1^+/+^* control and mutant *Acvr1^R206H/+^* MEFs. When cultured on tissue culture plastic, which presents a very stiff substrate ([@B1]), Rho activation was more robustly increased in *Acvr1^R206H/+^* cells compared with controls ([Figure 4A](#F4){ref-type="fig"}). RhoA, a small GTPase, regulates its kinase effector ROCK to influence actin filament stability and cytoskeletal organization and contractility by controlling the activity of its downstream targets cofilin and myosin light chain 2 (MLC2) ([@B78]; [@B63]; [@B89]). Cofilin affects cytoskeletal organization and dynamics by acting as a severing and disassembling protein of actin filaments; Rho/ROCK-mediated signaling phosphorylates and inactivates cofilin, thereby stabilizing actin-myosin filaments ([@B27]). Rho signaling through ROCK can induce contractility of the actomyosin cytoskeleton either by directly activating MLC2 through phosphorylation or indirectly by inhibiting its antagonist myosin-light-chain phosphatase ([@B78]). Consistent with increased Rho activation, *Acvr1^R206H/+^* cells showed elevated levels of phospho-Cofilin ([Figure 4B](#F4){ref-type="fig"}) and phospho-MLC2 ([Figure 4C](#F4){ref-type="fig"}) compared with controls, confirming overactivation of this mechanotransduction pathway in mutant cells cultured on rigid substrates.

![Increased signaling through mechanosensing pathways in *Acvr1^R206H/+^* cells. (A) Increased activation of mechanotransduction in *Acvr1^R206H/+^* (FOP) cells was determined by immunoblot for Rho after pull down of the active form (*n* = 6). Active Rho protein was normalized to total Rho. (B, C) Detection of RhoA downstream targets cofilin by immunoblot for pCofilin (*n* = 5) and MLC2 by immunostaining for pMLC2 showed increased levels in *Acvr1^R206H/+^* cells. pCofilin was normalized to total cofilin protein. Quantification of mean intensity of pMLC2 staining from three independent experiments normalized to cell area (*Acvr1^+/+^ n* = 61 *Acvr1^R206H/+^ n* = 91). Scale bar represents 50 μm. Graphs represent mean ± SEM. Significance was determined by two-tailed Student\'s *t* test; \**p* \< 0.05; \*\*\**p* \< 0.001.](mbc-30-17-g004){#F4}

Nuclear stiffness also has been shown to scale with substrate rigidity ([@B91]) and can be measured by AFM indentation of the cell in the perinuclear region ([Figure 5A](#F5){ref-type="fig"}), with this measurement of nuclear stiffness being a strong indicator of the overall contractile state of the cell ([@B91]). Consistent with changes in the bulk contractile state of the cells, *Acvr1^R206H/+^* MEF cells on rigid substrates showed increased nuclear stiffness compared with *Acvr1^+/+^* controls ([Figure 5B](#F5){ref-type="fig"} and Supplemental Material 2). Nuclear height also decreases as a function of cytoskeletal contraction on two-dimensional culture substrates ([@B97]) due to the increased contractility of the perinuclear actin cytoskeleton that compacts the nucleus. We found significant flattening of *Acvr1^R206H/+^* nuclei in comparison to control cells ([Figure 5C](#F5){ref-type="fig"}, left). This nuclear flattening was rescued by reducing cellular contractility through treatment with the ROCK inhibitor Y-27632 (Y27) ([Figure 5C](#F5){ref-type="fig"}, right), supporting that an inherently higher baseline contractility causes changes in the nuclear height/morphology of *Acvr1^R206H/+^* cells, providing additional evidence of increased mechanical signaling activity in mutant cells. Taken together, these data indicate that the Rho/ROCK mechanotransduction pathway is overactivated in *Acvr1^R206H/+^* cells, supporting an altered biomechanical response and misinterpretation of the substrate as a contributing mechanism to FOP pathology.

![Increased nuclear stiffness and altered nuclear height in *Acvr1^R206H/+^* cells. (A) Schematic of nuclear stiffness measurement by AFM. (B) Quantification of nuclear stiffness determined by AFM indicates higher stiffness in *Acvr1^R206H/+^* cells compared with controls (*Acvr1^+/+^*) (both *n* = 20). (C) Nuclear height in MEFs was determined by confocal microscopy, before (untreated) and after treatment with 10 μM Y-27632 (Y27), a ROCK inhibitor, for 1 h (*n* = 15--20 cells/group). Untreated *Acvr1^R206H/+^* cells show nuclear flattening (relative to control cells; i.e., negative value: *Acvr1^+/+^*: *n* = 15; *Acvr1^R206H/+^*: *n =* 20). The flattened morphology was rescued by reducing cellular contractility with the ROCK inhibitor Y-27632 (*Acvr1^+/+^*: *n* = 18 *Acvr1^R206H/+^*: *n* = 19). Scale bar represents 10 µm. Graphs represent mean ± SEM. Statistical significance was determined by two-tailed Student\'s *t* test, \*\*\**p* \< 0.001 (in B); or one-way ANOVA, \**p* \< 0.05, \*\*\**p* \< 0.001; Bonferroni\'s post hoc (in C).](mbc-30-17-g005){#F5}

Acvr1^R206H/+^ cells misinterpret substrate rigidity
----------------------------------------------------

The above studies, conducted on tissue culture plastic, support increased activation of mechanotransduction pathways by *Acvr1^R206H/+^* cells. Such stiff substrates inherently increase mechanosignaling ([@B104]; [@B45]; [@B92]; [@B94]; [@B107]) and may mask differences by activating pathways that are normally quiescent on a physiologic (softer) stiffness. To further test altered stiffness sensing by *Acvr1^R206H/+^* cells, we used a polyacrylamide (PA)-hydrogel culture system to produce physiologically-stiff substrates with rigidities that mimic the mechanical properties of various tissues ([@B32]; [@B3]; [@B49]). Thin layers of PA-hydrogels (*h* = 100 μm) were polymerized onto glass slides followed by coating with fibronectin to facilitate cell attachment. Hydrogel stiffness was controlled by acrylamide content, and the resulting stiffness verified by AFM force spectroscopy. Since cell--cell contacts can override cell-ECM-induced mechanosignaling ([@B68]), fibroblasts were seeded at low cell densities.

Response to the underlying substrate was quantified by measuring cell area and cell shape (aspect ratio) following cytoskeleton staining with phalloidin. As expected, both morphological parameters scale with substrate rigidity in *Acvr1^+/+^* control cells, as determined by increased cell spreading (greater cell area and less circular shape) with increasing substrate stiffness ([Figure 6, A and B](#F6){ref-type="fig"}). In contrast, *Acvr1^R206H/+^* cells showed reduced responsiveness to substrate stiffness as evidenced by the consistently higher cell size and morphology of the mutant cells across increasing rigidity. Overall, *Acvr1^R206H/+^* cells exhibited significantly greater cell areas and spreading compared with control cells; this was most pronounced for *Acvr1^R206H/+^* cells on softer matrices (5 kPa) which exhibited spread areas similarly to control cells on much stiffer substrates (15 kPa). These findings indicate that, in addition to creating a stiffer tissue microenvironment in FOP lesions, *Acvr1^R206H/+^* cells may also misinterpret and/or be less sensitive to the mechanical cues provided by their tissue environment during injury, inducing progenitor populations to follow abnormal lineage commitment pathways.

![*Acvr1^R206H/+^* cells misinterpret substrate elasticity. (A) Immortalized control and *Acvr1^R206H/+^* (FOP) cells on gels of various rigidities (5, 10, 15, and 55 kPa) were stained with phalloidin and DAPI. (B) Cell area and aspect ratio (AR) were measured as a function of matrix elasticity. Graphs represent mean ± SEM of \>350 cells from four independent experiments. Significance was determined by two-way ANOVA (comparison between genotypes; Tukey--Kramer adjustment; ^\#^*p* \< 0.05, ^\#\#\#^*p* \< 0.001, NS = not significant) or one-way ANOVA (comparison between substrate stiffness; ^\*\*\*^*p* \< 0.001; Bonferroni\'s post hoc). Scale bar represents 100 µm.](mbc-30-17-g006){#F6}

To investigate whether altered mechanosensing is associated with an osteogenic response in *Acvr1^R206H/+^* cells on softer substrates, we examined a key pro-osteoblast factor runt related transcription factor 2 (RUNX2; alias: CBFA1) that has been shown to be essential during early commitment of mesenchymal stem cells to the osteogenic lineage ([@B31]; [@B59]; [@B73]; [@B58]). Nuclear localization of RUNX2 is critical for its ability to act as a transcription factor to induce the expression of genes required for osteogenesis such as alkaline phosphatase, osteocalcin, and osterix ([@B59]; [@B105]; [@B2]). Previous work has shown that matrix stiffness regulates the nuclear localization of this factor in stem cells ([@B106]; [@B20]), with stiffer substrates promoting more nuclear localization.

*Acvr1^+/+^* control and mutant *Acvr1^R206H/+^* MEFs were cultured on PA-hydrogels of various stiffnesses for 18 h, immunostained for RUNX2 protein localization ([Figure 7A](#F7){ref-type="fig"}), and quantified for nuclear:cytoplasmic localization ratios of RUNX2 ([Figure 7B](#F7){ref-type="fig"}). We found that on all substrate stiffnesses tested, RUNX2 nuclear localization was higher in *Acvr1^R206H/+^* compared with *Acvr1^+/+^* control cells ([Figure 7B](#F7){ref-type="fig"}). Differences were most pronounced on 10 kPa, a stiffness comparable to normal muscle tissue ([@B32]). Since heterotopic bone forms within skeletal muscle tissue in patients with FOP, the difference in RUNX2 protein localization at 10 kPa stiffness may be functionally relevant. Taken together, these data strongly support that *Acvr1^R206H/+^* cells misinterpret their biophysical microenvironment, which leads to important changes in key factors that direct cellular differentiation and extracellular matrix production.

![RUNX2 nuclear localization is increased in FOP cells. (A) Immortalized *Acvr1^+/+^* control and *Acvr1^R206H/+^* cells on substrates of various rigidities (5, 10, 15, and 55 kPa) were detected for RUNX2 (green), phalloidin (red), and DAPI (blue). Nuclear localization of RUNX2 protein indicates activation of osteogenic cell fate programming. Scale bar represents 50 μm. (B) Relative nuclear localization of RUNX2 was quantified by the ratio of nuclear/cytoplasmic staining. Intensity shows that *Acvr1^R206H/+^* cells have more nuclear RUNX2 on softer substrates compared with *Acvr1^+/+^* control cells. Nuclear localization on stiffer substrates does not differ significantly between the genotypes, as expected. Graph represents mean ± SEM. Assay was repeated in three independent experiments (*n* = 50 cells per substrate stiffness per experiment). Statistical significance relative to *Acvr1^+/+^* controls at a given substrate stiffness (^\*\*^*p* \< 0.01, ^\*\*\*^*p* \< 0.001) or comparison between genotypes (^\#^*p* \< 0.05, ^\#\#\#^*p* \< 0.001) were determined by one-way ANOVA (Bonferroni\'s post hoc).](mbc-30-17-g007){#F7}

DISCUSSION
==========

Heterotopic ossification in the rare genetic disorder FOP, as well as in more common nonhereditary HO, forms through a progressive series of tissue/cellular events that culminate in bone formation within skeletal muscle and other connective tissues in response to tissue injury ([@B54]; [@B86]; [@B19]). During normal response to injury, resident fibroblasts at the wound site become activated myofibroblasts and this fibroproliferative stage is followed by the recruitment of muscle stem cells to regenerate muscle tissue ([@B15]). In the presence of the *ACVR1^R206H^* mutation, injury triggers the removal of damaged tissue and stimulates fibroproliferation, but cartilage and bone tissue subsequently form at the expense of muscle regeneration ([@B86]; [@B19]). The cellular response during this fibroproliferative tissue stage therefore may provide key insight into the cellular mechanisms that regulate heterotopic ossification. Cell fate is regulated by multiple factors including extracellular ligands, such as BMPs, and physical/mechanical signals from the cell microenvironment, such as the stiffness of the surrounding tissue ([@B32]; [@B99]; [@B28]; [@B82]; [@B29]).

All cells sense physical cues, including the stiffness of their environment. When these biophysical cues change, cell phenotype has the potential to be altered as a result ([@B37]; [@B48]). In this study, we investigated whether the *Acvr1^R206H/+^* mutation additionally influences the physical properties of tissues and/or the cell response to the tissue microenvironment. Such changes could provide the permissive conditions that support subsequent progression of aberrant cell differentiation to heterotopic bone and could provide novel targets for therapeutic intervention.

Using an in vivo model (*Acvr1^R206H/+^* knock-in mouse) of injury-induced heterotopic ossification and AFM to directly measure the physical stiffness of the tissue, we determined that the FOP mutation results in the aberrant production of a stiff, fibrotic-like environment at an early stage of repair and prior to the production of ectopic bone by mutant tissue. Our data suggest that *Acvr1^R206H/+^* cells involved in tissue repair establish a microenvironment that favors heterotopic bone formation.

ECM organization and composition, notably of collagens, are key determinants of tissue stiffness, and we determined that the fibroproliferative tissue in FOP lesions was organized to a greater extent than tissue in control lesions. Type I and type III collagens were detected at similar levels in *Acvr1^R206H/+^* and *Acvr1^+/+^* control lesions. However, type II collagen, which is usually restricted to specific tissues such as cartilage and is an established secondary target gene of the BMP signaling pathway ([@B72]; [@B6]; [@B71]) was increased only in mutant repair tissue, consistent with overactivation of the BMP signaling pathway by the *Acvr1^R206H/+^* mutation. In cartilage, the type II collagen network traps negatively charged proteoglycan aggregates that imbibe water into the tissue generating compressive stiffness ([@B9]; [@B67]) and therefore type II collagen in *Acvr1^R206H/+^* lesions may also cause increased stiffening in part by increasing hydration/swelling of lesion tissue and/or improper accumulation of proteoglycans.

Cells interpret the biophysical properties of their surroundings via cell surface mechanoreceptors that are coupled to the contractile cytoskeleton and signal through several direct and indirect signaling pathways that direct cell fate through modification of chromatin organization and gene expression ([@B4]; [@B91]; [@B88], [@B89]). We determined that the Rho/ROCK mechanosignaling pathway, which mediates signals from the extracellular matrix, integrins, and focal adhesions that affect cellular morphology, migration, contractility, and adhesion to surface substrates ([@B63]), is overactivated in cells with the *Acvr1^R206H/+^* mutation and that mutant cells additionally show increased nuclear and cellular stiffness, supporting that they do not correctly sense and interpret physical/mechanical cues from their tissue microenvironment. RhoA also facilitates phosphorylation of Smad1/5/8 ([@B26]; [@B30]; [@B101]; [@B60]), creating a further connection between RhoA activation and BMP signaling, two critical pathways that impact cell fate. Given the association between RhoA and osteogenic commitment ([@B4]), our data suggest that RhoA and BMP pathways might act synergistically to contribute to chondrogenic and osteogenic differentiation and endochondral ossification in FOP.

*Acvr1^R206H/+^* cells mesenchymal progenitor cells incorrectly sensed and interpreted substrate stiffness, responding with a considerably spread morphology on even very soft substrates. Strikingly, this response to the physical/mechanical environment was accompanied by increased nuclear localization of RUNX2, a chondro/osteogenic transcription factor ([@B59]; [@B105]; [@B100]; [@B16]; [@B2]). BMPs induce expression of RUNX2 ([@B41]; [@B69]; [@B90]) and RUNX2 nuclear localization is positively affected by increased mechanical force ([@B108]; [@B106]; [@B51]; [@B20]), supporting that increased BMP-pSmad1/5/8 signaling by the mutant *Acvr1^R206H^* receptor together with misinterpretation of microenvironment contribute to aberrant chondro/osteogenic differentiation by *Acvr1^R206H/+^* cells.

This study identifies for the first time that the FOP mutation alters cell mechanical state and mechanobiology, as well as the material properties of the wound microenvironment. We found that FOP cells are less sensitive to changing physical/mechanical features than control cells and that FOP tissue healing causes wounded muscle tissue to repair in a manner that is stiffer and more organized than normally occurs during skeletal muscle injury. These data support that the physical tissue microenvironment in which heterotopic ossification forms is both altered by cells with the *ACVR1^R206H^* mutation and is differentially perceived by cells with the *ACVR1^R206H^* mutation. We additionally propose that initial small-scale changes in the ECM (such as collagen type II production) act to prime formation of a stiffer tissue microenvironment. That is, BMP pathway signaling by the Acvr1^R206H^ mutation alters the repair trajectory of injured tissue, with cells interpreting softer matrices as stiffer. As tissue resident mesenchymal cells, such as the FAPs that have recently been identified as a major source of HO forming cells in a mouse model of FOP ([@B61]), begin to respond to the stiffer environment in the context of enhanced BMP pathway signaling, a reinforcing feedback loop results. This furthers ECM production and tissue stiffening (a situation that alone is pathologic, such as in fibrosis), but in the context of increased BMP signaling and altered biomechanical sensing, the cells are directed to differentiate to form heterotopic bone.

A novel treatment strategy to prevent HO formation in FOP patients, and potentially more common, nonhereditary forms of HO, may reside in the regulation of mechanotransduction pathways during tissue repair (e.g., Fasudil \[selective ROCK inhibitor\], Cethrin \[Rho inhibitor\]) ([@B84]; [@B65]; [@B33]; [@B5]; [@B109]). Our findings of biomechanical cues are important to consider in light of a recent therapeutic approach that has been successfully used in animal models to ameliorate fibrosis and also suggested to treat solid tumors that show increased stiffness and mechanical properties ([@B50]; [@B52]). Taken together, our data reveal the importance of mechanobiological signaling in FOP cells and provide the first direct experimental evidence that FOP progression may be influenced by the tissue microenvironment. Further studies will investigate the dependence on an altered physical environment to support heterotopic ossification, altered mechanosensing by progenitor cells, and the effects of inhibitors of biomechanical effectors on chondro/osteogenic differentiation in *Acvr1^R206H/+^* cells.

MATERIALS AND METHODS
=====================

Mouse strain and animal care and use
------------------------------------

Cells (MEFs) for in vitro experiments were obtained from *Acvr1^R206H/+^* knock-in mice described in [@B13].

Tissues for in vivo studies were obtained from *Acvr1^\[R206H\]FlEx^* conditional-on knock-in mice ([@B39]; [@B12]) that were bred to include R26-rtTA and tetO-Cre as described ([@B12]; [@B19]). Here we refer to these mice as *Acvr1^R206H/+^*. Acvr1^+/+^ controls were littermates that did not contain an Acvr1^R206H^ allele (as verified via PCR genotyping). To induce recombination and global expression of the mutant allele, 4-wk-old mice were provided a doxycycline diet (either 200 or 625 mg/kg) for at least three consecutive days. Cre-mediated recombination was verified by PCR. Littermate Acvr1^+/+^ controls were also treated with doxycycline. Mice were not assigned to treatment groups by gender in our experiments.

Induction of lesions in muscle tissue
-------------------------------------

Mouse quadriceps muscles were injected with 100 μl CTX solution (10 μM in phosphate-buffered saline \[PBS\]; Calbiochem). Muscle injury by CTX injection is a standard experimental approach in muscle regeneration studies ([@B21]; [@B15]; [@B98]; [@B24]). PBS injection in *Acvr1^R206H/+^* and *Acvr1^+/+^* littermates served as controls. This approach for injury induction of HO has been well characterized ([@B12]; [@B19]), with heterotopic bone forming at 10--14 d and robust fibroproliferation at 4--5 d. Animals were killed at the fibroproliferative stage to isolate lesion tissue and surrounding skeletal muscle. Tissues were embedded in optimal cutting temperature media (OCT; CryoPrep; American MasterTech Scientific) and serially sectioned at 20-μm thickness for AFM analysis or 10 μm for histology and immunohistochemistry.

Histology and collagen immunohistochemistry
-------------------------------------------

Tissues were fixed in 4% paraformaldehyde (PFA) in PBS (Fisher Scientific), sectioned to 10 μm, and stained with Harris modified hematoxylin and eosin Y (H&E) or used for immunohistochemistry.

For collagen detection, endogenous peroxidases were quenched by incubation with 3% hydrogen peroxidase solution. Sections were blocked (Background Buster; American MasterTech) and incubated overnight at 4°C with primary antibody against collagen type I and II (Abcam; catalogue ab34710 and ab21291, respectively), collagen type III (Thermo Scientific; catalogue PA5-27828), or IgG control (Cell Signaling Technology; catalogue 3900). After incubation with HRP-linked secondary anti-rabbit antibody (Cell Signaling Technology; catalogue 7074), signal was visualized by using 3,3'-diaminobenzidine (DAB) substrate (SuperPicTure Polymer; Invitrogen). Sections were counterstained by short incubation with hematoxylin (Vector Laboratories) or by DAPI using Fluoromount-G (SouthernBiotech). Imaging was carried out using an Eclipse 90i microscope (Nikon).

Analysis of tissue and cellular stiffness using atomic force microscopy
-----------------------------------------------------------------------

Tissue and nuclear stiffness were measured via nanoindentation using an atomic force microscope equipped for simultaneous optical imaging (Agilent ILM 6000 mounted on a Nikon inverted microscope) ([@B79]; [@B93]; [@B42]). For tissue analysis, unfixed 20-μm cryosections were hydrated and probed using cantilevers with 1-μm spherical tips and a nominal spring constant of a 0.6 N/m (Novascan). For each location measured, four force curves were collected over a 15 μm × 15 μm region that was visually identified as healthy muscle, degrading muscle, or fibroproliferative lesion tissue. For nuclear measurements, the AFM stage was maintained at 37°C. Cells were probed using silicon nitride cantilevers with 1 μm spherical tips and a nominal spring constant of 0.06 N/m (Novascan); force maps of up to 16 force curves were collected above the cell nucleus. For all measurements, actual cantilever spring constants were determined via the thermal fluctuation method. For both tissue and cell measurements, the first 300 nm of indentation was fitted using a Hertzian contact model to estimate stiffness (elastic modulus). After applying the Grubbs' test for outliers, estimated moduli were averaged over each tissue location or cell and considered as one data point.

Second-harmonic generation
--------------------------

To visualize collagen organization, SHG imaging ([@B38]) of unstained, unfixed 20-μm cryosections was performed using an excitation wavelength of 800 nm (Zeiss LSM 510 with tunable Ti-Sapphire laser). Signal collected between 390 and 465 nm was considered to be SHG specific, while signal collected between 500 and 550 nm was considered to be nonspecific tissue autofluorescence and used as a control. To semiquantitatively assess SHG images (*n* = 7--8 per genotype), four scorers blinded to genotype scored images on a categorical scale from highly organized (score = 5) to completely disorganized (score = 1). For each image, scores were averaged and considered as a single data point that is shown in the [Figure 3D](#F3){ref-type="fig"} boxplot; genotype score was compared using a Student\'s *t* test.

Preparation of polyacrylamide hydrogels
---------------------------------------

Rigidity of native tissues was mimicked using an adjustable PA hydrogel system. PA hydrogels were prepared as described ([@B3]). Elastic moduli of the gels were verified through AFM force spectroscopy. Fibronectin (20 mg/ml) coating of gel surfaces was accomplished after treatment with 2 mg/ml sulfo-SANPAH (No. 22589; Pierce Protein Biology/Life Technologies, Rockford, IL) as described previously ([@B3]).

Cell culture, mouse embryonic fibroblasts, and in vitro assays
--------------------------------------------------------------

Knock-in *Acvr1^R206H/+^* MEFs were isolated at embryonic day 13.5 (E13.5) as previously described ([@B23]) from mice described in [@B13] and from wild-type *Acvr1^+/+^* mice. Cells were immortalized (Capital Biosciences, Rockville, MD) by transducing cells with recombinant lentivirus expressing SV40 large T antigen. Expression of SV40 T antigen was confirmed via quantitative reverse transcription PCR (qRT-PCR). Genotypes of immortalized cell lines (iMEFs) and presence of the R206H mutation were confirmed by DNA sequencing. Cells were cultured in high glucose DMEM (Life Technologies) containing 10% fetal calf serum (FCS; Invitrogen). Testing for mycoplasma contamination was done after immortalization and repeated at the beginning of cultivation.

For nuclear height measurement, iMEFs were cultured in a standard growth medium (HG-DMEM, 10% FCS, 1% penicillin/streptomycin/fungiezone \[PSF\]), before treatment with ROCK inhibitor Y-27632 (Calbiochem; catalogue 688000) at 10 µM for 1 h. Following treatment, cells were fixed with 4% PFA, permeabilized with TX-100, and stained with DAPI. Nuclei (15--20 cells per condition) were imaged using a 100× 1.45 NA objective with a 1.7× zoom (0.07 μm/px) and a pinhole of 0.15 μm (0.5 AU) on a Nikon A1R Confocal Microscope. Measurements of nuclear height were determined from maximum projection XZ sections using the ImageJ software suite.

For mechanosensing assays, subconfluent iMEFs were seeded onto freshly prepared PA-hydrogels (described above) at a concentration of 5 × 10^3^ cells/cm^2^. After 16 h, cells on hydrogels were fixed in 4% paraformaldehyde/PBS (Affymetrix), followed by incubation with Alexa Fluor 488 Phalloidin (Invitrogen; catalogue A12379) to visualize the actin cytoskeleton and DAPI for nucleus staining. Cell contractility was visualized with primary pMLC2 antibody (Cell Signaling Technologies; catalogue 3674) followed by detection with AlexaFluor 594 anti-rabbit antibody (Invitrogen; catalogue A22107MP). RUNX2 protein localization was visualized with primary RUNX2 antibody (Cell Signaling; catalogue 12556; 1:800), followed by detection with Alexa Fluor 488 anti-rabbit antibody (Invitrogen; catalogue A12379; 1:1000); Alexa Fluor 546 phallodin (Invitrogen; catalogue A22283; 1:1000) was used to label F-actin simultaneously. Slides were mounted with DAPI Fluoromount-G (SouthernBiotech). Imaging used an Eclipse 90i microscope (Nikon) at consistent exposure times. Cell morphology was analyzed in ImageJ.

RUNX2 localization data were obtained through imaging immunostained cells (Eclipse 90i microscope; Nikon). Nuclear images were utilized to delineate the nuclear area from the cytoplasmic region, and the average fluorescent intensity over each region was calculated using ImageJ.

For collagen staining, cells were seeded in quadruplicates into a 96-well format at 2 × 10^3^ cells/well. Total tissue collagen was detected (Sirius Red/Fast Green collagen staining kit; Chondrex; catalogue 9046). After imaging, incorporated dyes were extracted and measured at OD~540~ (for collagen) and OD~605~ (for noncollagen protein). Collagen content was calculated as μg/well following manufacturer\'s instructions.

Western blotting
----------------

Cells were lysed in buffer (RIPA; Sigma-Aldrich) supplemented with Halt Protease and Halt Phosphatase Inhibitor Cocktails (Pierce), cleared by centrifugation and quantified using BCA Protein Kit (Thermo Scientific). Proteins were electrophoresed through 10% Tris--glycine gels (Invitrogen) and transferred onto a nitrocellulose membrane (Invitrogen). Membranes were blocked in 5% milk in Tris-buffered saline (TBS) and incubated overnight at 4°C with primary antibody for cofilin, phospho-Cofilin, and β-actin (all Cell Signaling Technology; catalogue 5175, 3313, and 4967, respectively) followed by detection using a HRP-conjugated secondary antibody (Cell Signaling Technology; catalogue 7074). Membranes were incubated with HRP substrate (LI-COR) and chemiluminescence was detected and quantified with a C-DiGit Blot Scanner (LI-COR). Phospho- and total cofilin values were first normalized to β-actin to correct for variation in protein loading, followed by normalization of phospho- to total cofilin and, finally, to *Acvr1^+/+^* control cells.

Rho activity assay
------------------

Cells were cultured to confluence in 15-cm plates to obtain sufficient protein amounts for active Rho pull down. Cell lysis and pull down of active Rho used 550 μg of total protein following manufacturer\'s instructions (Active Rho Pull-Down and Detection Kit; Thermo Scientific; catalogue 16116). Proteins were electrophoresed through 10% Tris--glycine gels (Invitrogen), transferred onto nitrocellulose membranes (Invitrogen) and detected with anti-Rho antibody. Additional blots for total Rho and β-actin were run for all samples as loading controls.

RNA isolation and real-time RT-PCR analysis
-------------------------------------------

RNA was isolated from MEF monolayers using TRIzol (Invitrogen). Genomic DNA was eliminated from RNA samples by digestion with RNase-free DNase (Promega). RNA concentration was determined by NanoDrop and equivalent amounts for each sample were used for cDNA synthesis using High Capacity RNA-to-cDNA reagents (Applied Biosystems). Quantitative PCR analysis was performed to detect expression of collagen type I alpha 1 chain (Col1a1), collagen type II alpha 1 chain (Col2a1), and collagen type III alpha 1 chain (Col3a1) in a 7500 thermal cycler (Applied Biosystems) using forward and reverse primers (Col1a1 forward 5′-GCATGGCCAAGAAGACATCC-3′; Col1a1 reverse 5′-CCTCGGGTTTCCACGTCTC-3′; Col2a1 forward 5′-AGAACAGCATCGCCTACCTG-3′; Col2a1 reverse 5′-CTTGCCCCACTTACCAGTGT-3′; Col3a1 forward 5′-TCAAGTCTGGAGTGGGAGG-3′; Col3a1 reverse 5′-TCCAGGATGTCCAGAAGAACCA-3′) and Fast SYBR Green PCR Master Mix (Applied Biosystems). Each sample was run in triplicate and normalized to GAPDH followed by normalization to respective collagen content of *Acvr1^+/+^* on day 1.

Statistical analysis
--------------------

Results are presented as the mean ± SEM. Paired or unpaired data sets were analyzed using two-tailed Student\'s *t* test or analysis of variance (ANOVA) (Bonferroni or Tukey--Kramer post-hoc test; one-way or two-way) to determine significance. Differences were considered statistically significant at *p* \< 0.05. Significance and sample size (*n* for number in group or *N* for total sample size) are shown for each data set in the figure legends.

Study approval
--------------

All procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the University of Pennsylvania.
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ACVR1

:   Activin A receptor, type 1

BMP

:   bone morphogenetic protein

ECM

:   extracellular matrix

FOP

:   fibrodysplasia ossificans progressiva

HO

:   heterotopic ossification

MEF

:   mouse embryonic fibroblast

PA

:   polyacrylamide

RhoA

:   ras homologue gene family, member A

ROCK

:   Rho-associated protein kinase

RUNX2

:   runt-related transcription factor 2
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